skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction

Review

(2000) Views  (900) Full article downloads

Authors: Ikechi G Okpechi, Brian L Rayner

Published Date May 2010 Volume 2010:3 Pages 45 - 55
DOI: http://dx.doi.org/10.2147/IBPC.S9963

Ikechi G Okpechi, Brian L Rayner

Department of Medicine, Division of Nephrology and Hypertension, Groote Schuur Hospital and University of Cape Town, Observatory, Cape Town 7925, South Africa

Abstract: Hypertension is the most prevalent cardiovascular disease of adults and is a major risk factor for cardiovascular (CV) and cerebrovascular morbidity and mortality worldwide. Treatment of hypertension leads to reduction of CV morbidity and mortality through blood pressure reduction. The role of renin–angiotensin–aldosterone system (RAAS) in the pathophysiology of hypertension is mainly through generation of potent vasoconstrictor angiotensin II, stimulation of aldosterone secretion, and increase in sympathetic activation. Angiotensin II receptor blockers such as candesartan, a long-acting agent, alter this system by blocking the activation of angiotensin I receptors. Several important clinical trials have tested the efficacy of candesartan with placebo, antihypertensive agents, or other agents that block the RAAS for the control of hypertension and reduction of key CV risk factors such as microalbuminuria, heart failure, retinopathy, and carotid intima medial thickness. Candesartan has been shown to be a welltolerated and effective antihypertensive agent with positive metabolic characteristics and additional benefits on CV and cerebrovascular outcomes. The aim of this review is to discuss the pharmacology, efficacy, and safety of candesartan, with an overview of key hypertension and CV studies involving candesartan.

Keywords: ACE inhibitor, ARB, blood pressure, treatment, heart








Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
De-stiffening drug therapy and blood pressure control
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Evidence-based approach for managing hypertension in type 2 diabetes
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness
Impact of telmisartan in modifying vascular risk
Long-term use and tolerability of irbesartan for control of hypertension
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University